These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 1088246)

  • 1. Approaches to selectivity in cancer chemotherapy.
    Bertino JR
    Adv Pathobiol; 1976; 2():65-9. PubMed ID: 1088246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical factors in the selectivity of leucovorin rescue: selective inhibition of leucovorin reactivation of dihydrofolate reductase and leucovorin utilization in purine and pyrimidine biosynthesis by methotrexate and dihydrofolate polyglutamates.
    Goldman ID; Matherly LH
    NCI Monogr; 1987; (5):17-26. PubMed ID: 2448654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Searching for magic bullets: early approaches to chemotherapy-antifolates, methotrexate--the Bruce F. Cain memorial award lecture.
    Jukes TH
    Cancer Res; 1987 Nov; 47(21):5528-36. PubMed ID: 3311354
    [No Abstract]   [Full Text] [Related]  

  • 4. Cancer chemotherapy: mechanisms of action.
    Conroy JF
    Semin Drug Treat; 1973; 3(1):5-14. PubMed ID: 4541416
    [No Abstract]   [Full Text] [Related]  

  • 5. Intracavitary therapy of murine ovarian cancer with cis-diamminedichloroplatinum(II) and 10-ethyl-10-deazaaminopterin incorporating systemic leucovorin protection.
    Sirotnak FM; Schmid FA; DeGraw JI
    Cancer Res; 1989 Jun; 49(11):2890-3. PubMed ID: 2785847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toward improved selectivity in cancer chemotherapy: the Richard and Hinda Rosenthal Foundation Award Lecture.
    Bertino JR
    Cancer Res; 1979 Feb; 39(2 Pt 1):293-304. PubMed ID: 310709
    [No Abstract]   [Full Text] [Related]  

  • 7. [Chemotherapy of malignant tumors with folic acid antagonists].
    Arzneimittelforschung; 1980; 30(11):1950-9. PubMed ID: 7193009
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase I study of high-dose methotrexate with thymidine and low-dose leucovorin.
    Bruno S; Grindey G; Zakrzewski S; Priore R; Kinahan J; Moayeri H; Ledesma E; Mittelman A; Creaven P
    Cancer Res; 1982 Nov; 42(11):4824-6. PubMed ID: 6982097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antifolate polyglutamylation and competitive drug displacement at dihydrofolate reductase as important elements in leucovorin rescue in L1210 cells.
    Matherly LH; Barlowe CK; Goldman ID
    Cancer Res; 1986 Feb; 46(2):588-93. PubMed ID: 2416428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approaches to drug selectivity in cancer therapy on the basis of differences between membranes of normal vs. neoplastic cells.
    Bertino JR
    Adv Pathobiol; 1980; 7():377-86. PubMed ID: 7405746
    [No Abstract]   [Full Text] [Related]  

  • 11. [Methotrexate-leucovorin rescue therapy: pharmacological characteristics and clinical effective use].
    Fujimoto T
    Gan To Kagaku Ryoho; 1996 Dec; 23(14):1901-6. PubMed ID: 8978794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective protection of normal proliferating cells against the toxic effects of chemotherapeutic agents.
    Keyomarsi K; Pardee AB
    Prog Cell Cycle Res; 2003; 5():527-32. PubMed ID: 14593747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methodology for the rational development of methotrexate analogs in the clinic.
    Leyland-Jones B; O'Dwyer PJ; Hoth DF; Wittes RE
    NCI Monogr; 1987; (5):93-7. PubMed ID: 3481041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomodulation of 5-fluorouracil with antifolates.
    Bertino JR
    Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-52-S18-56. PubMed ID: 9420021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Schedule-dependent synergism and antagonism between paclitaxel and methotrexate in human carcinoma cell lines.
    Kano Y; Akutsu M; Tsunoda S; Furuta M; Yazawa Y; Ando J
    Oncol Res; 1998; 10(7):347-54. PubMed ID: 10063968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifolate analogs: mechanism of action, analytical methodology, and clinical efficacy.
    Fleisher M
    Ther Drug Monit; 1993 Dec; 15(6):521-6. PubMed ID: 8122287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Vitamin B12 as a regulator and methotrexate as an antagonist of folic acid metabolism. Pathophysiologic and clinical aspects].
    Sauer H
    Fortschr Med; 1983 Apr; 101(15):705-10. PubMed ID: 6602086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of methotrexate-resistant human acute lymphoblastic leukemia cells in culture and effects of folate antagonists.
    Ohnoshi T; Ohnuma T; Takahashi I; Scanlon K; Kamen BA; Holland JF
    Cancer Res; 1982 May; 42(5):1655-60. PubMed ID: 6978176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein.
    Westerhof GR; Rijnboutt S; Schornagel JH; Pinedo HM; Peters GJ; Jansen G
    Cancer Res; 1995 Sep; 55(17):3795-802. PubMed ID: 7641196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trimetrexate as a biochemical modulator of 5-fluorouracil and leucovorin in colorectal cancer.
    Punt CJ
    Semin Oncol; 2000 Oct; 27(5 Suppl 10):88-90. PubMed ID: 11049038
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.